IDEXX Laboratories, Inc. (IDXX)
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Idexx (IDXX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes
Major U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday raised concerns about the resilience of the economy, the slowdown in hiring and uptick in unemployment could add to the case for upcoming interest-rate cuts by the Federal Reserve.
IDEXX Laboratories, Inc. (IDXX) Q2 2025 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - President, CEO & Director Conference Call Participants Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Erin Elizabeth Wilson Wright - Morgan Stanley, Research Division Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Navann Ty Dietschi - BNP Paribas Exane, Research Division Ryan Scott Daniels - William Blair & Company L.L.C.
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
Idexx (IDXX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IDEXX Laboratories Stock Jumps as Pet Health Care Firm Lifts Full-Year Outlook
Shares of IDEXX Laboratories (IDXX) soared more than 10% in premarket trading Monday after the pet health care company reported better-than-expected second-quarter results and raised its 2025 profit and revenue forecasts.
Idexx Laboratories (IDXX) Tops Q2 Earnings and Revenue Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $3.63 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.44 per share a year ago.
Idexx (IDXX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Idexx (IDXX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
